Stay updated on Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial
Sign up to get notified when there's something new on the Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial page.

Latest updates to the Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial page
- Check4 days agoChange DetectedThe study record is now displayed, including its design, eligibility criteria, locations, outcomes, publications, and supporting documents. It describes a completed Phase 3 trial evaluating a switch to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV-1.SummaryDifference76%

- Check11 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA banner announces NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence,” and the site revision identifier changes from v3.7.1 to v3.7.2. The study record itself remains unavailable behind a 403 error.SummaryDifference1%

- Check39 days agoChange DetectedThe site revision identifier changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error instead of study details.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now shows a 403 Forbidden error page, replacing the study record content and navigation with an error screen. The HTML snippet confirms an access denial, effectively blocking the study details from view.SummaryDifference16%

- Check60 days agoChange DetectedThe page revision label was updated from v3.6.6 to v3.7.0, indicating a back-end/content update to the page.SummaryDifference0.0%

Stay in the know with updates to Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial page.